All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
SAN FRANCISCO – The regenerative medicine sector is on the move thanks to positive clinical data readouts, strong investor interest during 2013 and big pharma now starting to get involved in the space. This momentum will only grow going forward. That was the message coming out of the Alliance for Regenerative Medicine’s (ARM) state of the industry briefing Monday at the Biotech Showcase meeting.